Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study

Sampath Kumar-Kandala Jeevan; Roshni Paul-Tara; Shantiveer Uppin; Megha Uppin; Kavitha Bali; Sundaram- Challa; Raghunadha Rao

doi:doi:10.11648/j.crj.20140205.13

Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study

Sampath Kumar-Kandala Jeevan, Roshni Paul-Tara, Shantiveer Uppin, Megha Uppin, Kavitha Bali, Sundaram- Challa, Raghunadha Rao

Published in Cancer Research Journal (Volume 2, Issue 5)

Received: 10 September 2014 Accepted: 17 September 2014 Published: 30 September 2014

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Follicular lymphoma (FL) is the most common indolent form of non Hodgkin lymphoma and characterized by initial response to treatment with inevitable relapse. Rituximab, is an anti CD20 monoclonal antibody, plays an important role in combination chemoimmunotherapy in treatment of symptomatic follicular lymphoma. Though rituximab is helpful in reducing the tumor burden in patients of follicular lymphoma, a significant proportion of patients were found to have resistance to rituximab and eventually progressed to high grade lymphoma. In this study we evaluated chemoimmunotherapy (CIR) resistant patients to know the incidence, predictive factors associated with CIR resistance and prognosis. This is a retrospective study, included 49 patients of follicular lymphoma, of these 12 (24.5%) demonstrated CIR resistance. On univariate analysis, high LDH values, advanced stage and high FLIPI score may predict the resistance of CIR therapy in initial stage of therapy. Overall, 7 patients (58.3%) progressed to high grade lymphoma (biopsy proven) and 2 (16.6%) died of disease progression in CIR resistant patients. Progressive free survival significantly reduced in CIR resistant patients (26 months) than CIR responders.

Published in	Cancer Research Journal (Volume 2, Issue 5)
DOI	10.11648/j.crj.20140205.13
Page(s)	93-97
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2014. Published by Science Publishing Group

Keywords

Chemoimmunotherapy Resistance, Follicular Lymphoma, FLIPI Score, Lactate Dehydrogenase, Advance Stage, Progression

References

[1]	Buske C, Gisselbrecht C, Gribben J, et al. Refining the treatment of follicular lymphoma: Leukemia and Lymphoma, 2008; 49:18-26.
[2]	Hiddemann W, Kneba M, Dreyling M, et al. – Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphomas compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2005; 106:3725-3732
[3]	Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 2011;377:42-51.
[4]	van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-3301.
[5]	Marinus H.J, Van Oers MH, Van Glabbeke M et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-2858.
[6]	Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95:3900-3908.
[7]	Macor P, Tripodo C, Zorzet S et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007;67:10556-10563.
[8]	Treon SP, Mitsiades C, Mitsiades N et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001;24:263-271.
[9]	Czuczman MS, Olejniczak S, Gowda A et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008;14:1561-1570.
[10]	Itala M, Geisler CH, Kimby E et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002; 69:129-134
[11]	Manches O, Lui G, Chaperot L et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949-954.
[12]	Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-758.
[13]	Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010; 51:983-994.
[14]	13. Al-Tourah AJ, Gill KK, Chhanabhai M et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.J Clin Oncol 2008;26:5165-5169.
[15]	Montoto S, Davies AJ, Matthews J et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25:2426-2433.
[16]	Bastion Y, Sebban C, Berger F et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15:1587-1594.
[17]	Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258-1265.
[18]	Swerdlow S, Campo E, Harris N et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2008.
[19]	L. Mozessohn, M.C. Cheung, M. Crump et al. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis. Leukemia & lymphoma 2014 Jan: (doi:10.3109/10428194.2014.885513).
[20]	Hatake K, Terui. Rituximab resistance in B-cell lymphoma and its elimination. Gan to kagaku ryoho cancer & chemotherapy; 2009 Apr; 36 (4):548-51.

Cite This Article

Plain Text BibTeX RIS

APA Style

Sampath Kumar-Kandala Jeevan, Roshni Paul-Tara, Shantiveer Uppin, Megha Uppin, Kavitha Bali, et al. (2014). Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study. Cancer Research Journal, 2(5), 93-97. https://doi.org/10.11648/j.crj.20140205.13

Copy | Download

ACS Style

Sampath Kumar-Kandala Jeevan; Roshni Paul-Tara; Shantiveer Uppin; Megha Uppin; Kavitha Bali, et al. Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study. Cancer Res. J. 2014, 2(5), 93-97. doi: 10.11648/j.crj.20140205.13

Copy | Download

AMA Style

Sampath Kumar-Kandala Jeevan, Roshni Paul-Tara, Shantiveer Uppin, Megha Uppin, Kavitha Bali, et al. Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study. Cancer Res J. 2014;2(5):93-97. doi: 10.11648/j.crj.20140205.13

Copy | Download

@article{10.11648/j.crj.20140205.13,
  author = {Sampath Kumar-Kandala Jeevan and Roshni Paul-Tara and Shantiveer Uppin and Megha Uppin and Kavitha Bali and Sundaram- Challa and Raghunadha Rao},
  title = {Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study},
  journal = {Cancer Research Journal},
  volume = {2},
  number = {5},
  pages = {93-97},
  doi = {10.11648/j.crj.20140205.13},
  url = {https://doi.org/10.11648/j.crj.20140205.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20140205.13},
  abstract = {Follicular lymphoma (FL) is the most common indolent form of non Hodgkin lymphoma and characterized by initial response to treatment with inevitable relapse. Rituximab, is an anti CD20 monoclonal antibody, plays an important role in combination chemoimmunotherapy in treatment of symptomatic follicular lymphoma. Though rituximab is helpful in reducing the tumor burden in patients of follicular lymphoma, a significant proportion of patients were found to have resistance to rituximab and eventually progressed to high grade lymphoma. In this study we evaluated chemoimmunotherapy (CIR) resistant patients to know the incidence, predictive factors associated with CIR resistance and prognosis. This is a retrospective study, included 49 patients of follicular lymphoma, of these 12 (24.5%) demonstrated CIR resistance. On univariate analysis, high LDH values, advanced stage and high FLIPI score may predict the resistance of CIR therapy in initial stage of therapy. Overall, 7 patients (58.3%) progressed to high grade lymphoma (biopsy proven) and 2 (16.6%) died of disease progression in CIR resistant patients. Progressive free survival significantly reduced in CIR resistant patients (26 months) than CIR responders.},
 year = {2014}
}

Copy | Download

TY  - JOUR
T1  - Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study
AU  - Sampath Kumar-Kandala Jeevan
AU  - Roshni Paul-Tara
AU  - Shantiveer Uppin
AU  - Megha Uppin
AU  - Kavitha Bali
AU  - Sundaram- Challa
AU  - Raghunadha Rao
Y1  - 2014/09/30
PY  - 2014
N1  - https://doi.org/10.11648/j.crj.20140205.13
DO  - 10.11648/j.crj.20140205.13
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 93
EP  - 97
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20140205.13
AB  - Follicular lymphoma (FL) is the most common indolent form of non Hodgkin lymphoma and characterized by initial response to treatment with inevitable relapse. Rituximab, is an anti CD20 monoclonal antibody, plays an important role in combination chemoimmunotherapy in treatment of symptomatic follicular lymphoma. Though rituximab is helpful in reducing the tumor burden in patients of follicular lymphoma, a significant proportion of patients were found to have resistance to rituximab and eventually progressed to high grade lymphoma. In this study we evaluated chemoimmunotherapy (CIR) resistant patients to know the incidence, predictive factors associated with CIR resistance and prognosis. This is a retrospective study, included 49 patients of follicular lymphoma, of these 12 (24.5%) demonstrated CIR resistance. On univariate analysis, high LDH values, advanced stage and high FLIPI score may predict the resistance of CIR therapy in initial stage of therapy. Overall, 7 patients (58.3%) progressed to high grade lymphoma (biopsy proven) and 2 (16.6%) died of disease progression in CIR resistant patients. Progressive free survival significantly reduced in CIR resistant patients (26 months) than CIR responders.
VL  - 2
IS  - 5
ER  -

Copy | Download

Author Information

Sampath Kumar-Kandala Jeevan

Department of Pathology, Nizam`s Institute of Medical Sciences, Hyderabad, India
Roshni Paul-Tara

Department of Pathology, Nizam`s Institute of Medical Sciences, Hyderabad, India
Shantiveer Uppin

Department of Pathology, Nizam`s Institute of Medical Sciences, Hyderabad, India
Megha Uppin

Department of Pathology, Nizam`s Institute of Medical Sciences, Hyderabad, India
Kavitha Bali

Department of Pathology, Osmania Medical College, Hyderabad, India
Sundaram- Challa

Department of Pathology, Nizam`s Institute of Medical Sciences, Hyderabad, India
Raghunadha Rao

Department of Medical Oncology, Nizam`s Institute of Medical Sciences, Hyderabad, India

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Sampath Kumar-Kandala Jeevan, Roshni Paul-Tara, Shantiveer Uppin, Megha Uppin, Kavitha Bali, et al. (2014). Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study. Cancer Research Journal, 2(5), 93-97. https://doi.org/10.11648/j.crj.20140205.13

Copy | Download

ACS Style

Sampath Kumar-Kandala Jeevan; Roshni Paul-Tara; Shantiveer Uppin; Megha Uppin; Kavitha Bali, et al. Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study. Cancer Res. J. 2014, 2(5), 93-97. doi: 10.11648/j.crj.20140205.13

Copy | Download

AMA Style

Sampath Kumar-Kandala Jeevan, Roshni Paul-Tara, Shantiveer Uppin, Megha Uppin, Kavitha Bali, et al. Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study. Cancer Res J. 2014;2(5):93-97. doi: 10.11648/j.crj.20140205.13

Copy | Download

@article{10.11648/j.crj.20140205.13,
  author = {Sampath Kumar-Kandala Jeevan and Roshni Paul-Tara and Shantiveer Uppin and Megha Uppin and Kavitha Bali and Sundaram- Challa and Raghunadha Rao},
  title = {Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study},
  journal = {Cancer Research Journal},
  volume = {2},
  number = {5},
  pages = {93-97},
  doi = {10.11648/j.crj.20140205.13},
  url = {https://doi.org/10.11648/j.crj.20140205.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20140205.13},
  abstract = {Follicular lymphoma (FL) is the most common indolent form of non Hodgkin lymphoma and characterized by initial response to treatment with inevitable relapse. Rituximab, is an anti CD20 monoclonal antibody, plays an important role in combination chemoimmunotherapy in treatment of symptomatic follicular lymphoma. Though rituximab is helpful in reducing the tumor burden in patients of follicular lymphoma, a significant proportion of patients were found to have resistance to rituximab and eventually progressed to high grade lymphoma. In this study we evaluated chemoimmunotherapy (CIR) resistant patients to know the incidence, predictive factors associated with CIR resistance and prognosis. This is a retrospective study, included 49 patients of follicular lymphoma, of these 12 (24.5%) demonstrated CIR resistance. On univariate analysis, high LDH values, advanced stage and high FLIPI score may predict the resistance of CIR therapy in initial stage of therapy. Overall, 7 patients (58.3%) progressed to high grade lymphoma (biopsy proven) and 2 (16.6%) died of disease progression in CIR resistant patients. Progressive free survival significantly reduced in CIR resistant patients (26 months) than CIR responders.},
 year = {2014}
}

Copy | Download

TY  - JOUR
T1  - Chemoimmunotherapy Resistant Follicular Lymphoma – A Single Institutional Study
AU  - Sampath Kumar-Kandala Jeevan
AU  - Roshni Paul-Tara
AU  - Shantiveer Uppin
AU  - Megha Uppin
AU  - Kavitha Bali
AU  - Sundaram- Challa
AU  - Raghunadha Rao
Y1  - 2014/09/30
PY  - 2014
N1  - https://doi.org/10.11648/j.crj.20140205.13
DO  - 10.11648/j.crj.20140205.13
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 93
EP  - 97
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20140205.13
AB  - Follicular lymphoma (FL) is the most common indolent form of non Hodgkin lymphoma and characterized by initial response to treatment with inevitable relapse. Rituximab, is an anti CD20 monoclonal antibody, plays an important role in combination chemoimmunotherapy in treatment of symptomatic follicular lymphoma. Though rituximab is helpful in reducing the tumor burden in patients of follicular lymphoma, a significant proportion of patients were found to have resistance to rituximab and eventually progressed to high grade lymphoma. In this study we evaluated chemoimmunotherapy (CIR) resistant patients to know the incidence, predictive factors associated with CIR resistance and prognosis. This is a retrospective study, included 49 patients of follicular lymphoma, of these 12 (24.5%) demonstrated CIR resistance. On univariate analysis, high LDH values, advanced stage and high FLIPI score may predict the resistance of CIR therapy in initial stage of therapy. Overall, 7 patients (58.3%) progressed to high grade lymphoma (biopsy proven) and 2 (16.6%) died of disease progression in CIR resistant patients. Progressive free survival significantly reduced in CIR resistant patients (26 months) than CIR responders.
VL  - 2
IS  - 5
ER  -

Copy | Download